Medicamen Biotech Limited has submitted a regulatory intimation to BSE Limited and National Stock Exchange of India Limited regarding an upcoming Board of Directors meeting. The meeting is scheduled for Friday, November 13, 2026, and will be held at the company's registered office at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi – 110019.
The primary agenda for the board meeting includes:
- Consideration and approval of the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026
- Any other business with the permission of the Chair
The company also disclosed that pursuant to its Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the company's shares has been closed for all designated persons since October 01, 2026. The trading window will reopen 48 hours after the financial results are declared to the stock exchanges.
This intimation is filed pursuant to Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The document was signed by Parul Choudhary, Company Secretary & Compliance Officer (ACS: 44157), and digitally timestamped on November 06, 2026 at 10:51:23 +05'30'.